2024 Q2 Form 10-Q Financial Statement
#000165495424006398 Filed on May 15, 2024
Income Statement
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
Revenue | $0.00 | $0.00 |
YoY Change | ||
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $874.6K | $1.603M |
YoY Change | -2.11% | 47.72% |
% of Gross Profit | ||
Research & Development | $2.009M | $1.601M |
YoY Change | 139.48% | 34.22% |
% of Gross Profit | ||
Depreciation & Amortization | ||
YoY Change | ||
% of Gross Profit | ||
Operating Expenses | $2.884M | $3.204M |
YoY Change | 66.46% | 40.65% |
Operating Profit | -$2.884M | -$3.204M |
YoY Change | 66.46% | 40.65% |
Interest Expense | $54.64K | $69.30K |
YoY Change | 75.97% | 84.6% |
% of Operating Profit | ||
Other Income/Expense, Net | $1.400M | |
YoY Change | ||
Pretax Income | -$2.829M | -$3.134M |
YoY Change | 66.29% | 39.91% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$2.829M | -$3.134M |
YoY Change | 66.28% | 39.91% |
Net Earnings / Revenue | ||
Basic Earnings Per Share | ||
Diluted Earnings Per Share | -$4.18 | -$0.47 |
COMMON SHARES | ||
Basic Shares Outstanding | 6.661M shares | 6.661M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $4.947M | $4.734M |
YoY Change | -41.37% | -46.0% |
Cash & Equivalents | $4.947M | $4.734M |
Short-Term Investments | ||
Other Short-Term Assets | $289.5K | $446.1K |
YoY Change | 5.81% | -14.54% |
Inventory | ||
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $5.237M | $5.180M |
YoY Change | -39.9% | -44.27% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | ||
YoY Change | ||
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | ||
YoY Change | ||
Total Long-Term Assets | $2.00 | -$4.00 |
YoY Change | 100.0% | -20.0% |
TOTAL ASSETS | ||
Total Short-Term Assets | $5.237M | $5.180M |
Total Long-Term Assets | $2.00 | -$4.00 |
Total Assets | $5.237M | $5.180M |
YoY Change | -39.9% | -44.27% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.327M | $822.5K |
YoY Change | 203.16% | 66.89% |
Accrued Expenses | $591.3K | $549.2K |
YoY Change | 141.25% | -23.1% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $1.918M | $1.372M |
YoY Change | 180.94% | 13.65% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | ||
YoY Change | ||
Total Long-Term Liabilities | $0.00 | $0.00 |
YoY Change | ||
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $1.918M | $1.372M |
Total Long-Term Liabilities | $0.00 | $0.00 |
Total Liabilities | $1.918M | $1.372M |
YoY Change | 180.94% | 13.65% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$59.35M | -$56.52M |
YoY Change | 19.82% | 18.16% |
Common Stock | $69.00 | $666.00 |
YoY Change | -78.37% | 178.66% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $3.318M | $3.808M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $5.237M | $5.180M |
YoY Change | -39.9% | -44.27% |
Cashflow Statement
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$2.829M | -$3.134M |
YoY Change | 66.28% | 39.91% |
Depreciation, Depletion And Amortization | ||
YoY Change | ||
Cash From Operating Activities | -$2.126M | -$2.704M |
YoY Change | 15.52% | 63.94% |
INVESTING ACTIVITIES | ||
Capital Expenditures | ||
YoY Change | ||
Acquisitions | ||
YoY Change | ||
Other Investing Activities | ||
YoY Change | ||
Cash From Investing Activities | ||
YoY Change | ||
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 2.339M | $0.00 |
YoY Change | 54.71% | -100.0% |
NET CHANGE | ||
Cash From Operating Activities | -2.126M | -$2.704M |
Cash From Investing Activities | ||
Cash From Financing Activities | 2.339M | $0.00 |
Net Change In Cash | 213.5K | -$2.704M |
YoY Change | -165.03% | -207.09% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$2.126M | -$2.704M |
Capital Expenditures | ||
Free Cash Flow | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1192633 | usd |
CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
1371766 | usd |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
1623616 | usd |
CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
666 | usd |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
393 | usd |
CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
60329464 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
59742503 | usd |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-56522140 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-53387878 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3807990 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6355018 | usd |
CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5179756 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
7978634 | usd |
CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
446075 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
540499 | usd |
CY2024Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
822546 | usd |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
866028 | usd |
CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1602819 | usd |
CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
3203560 | usd |
CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3203560 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
7978634 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1085049 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7438135 | usd |
CY2024Q1 | us-gaap |
Assets
Assets
|
5179756 | usd |
CY2024Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
549220 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
757588 | usd |
CY2024Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001853816 | |
CY2024Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2024Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
CY2024Q1 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | shares |
CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6660840 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3930840 | shares |
CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2024Q1 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0.0001 | |
CY2024Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2024Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2024Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-03-31 | |
CY2024Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2024Q1 | dei |
Entity File Number
EntityFileNumber
|
001-40739 | |
CY2024Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
DERMATA THERAPEUTICS, INC. | |
CY2024Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2024Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
86-3218736 | |
CY2024Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
3525 Del Mar Heights Rd | |
CY2024Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
#322 | |
CY2024Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | |
CY2024Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
CY2024Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92130 | |
CY2024Q1 | dei |
City Area Code
CityAreaCode
|
858 | |
CY2024Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
800-2543 | |
CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
6660840 | shares |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4733681 | usd |
CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6660840 | shares |
CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1600741 | usd |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2277682 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2277682 | usd |
CY2024Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
69298 | usd |
CY2023Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
37540 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3134262 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2240142 | usd |
CY2024Q1 | drma |
Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
|
-0.47 | |
CY2023Q1 | drma |
Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
|
-2.27 | |
CY2024Q1 | drma |
Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
|
6660840 | shares |
CY2023Q1 | drma |
Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
|
985848 | shares |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6355018 | usd |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
587234 | usd |
CY2024Q1 | drma |
Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
|
0 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3134262 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3807990 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6021854 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
131260 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4174985 | usd |
CY2024Q1 | drma |
Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
|
0 | usd |
CY2023Q1 | drma |
Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
|
153 | usd |
CY2023Q1 | drma |
Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
|
-40 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2240142 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8088070 | usd |
CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
3134262 | usd |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
2240142 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
587234 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
131260 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-94424 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-174848 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-43482 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3831 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-208368 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
288232 | usd |
CY2024Q1 | us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
429808 | usd |
CY2023Q1 | us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
590509 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2704454 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1649633 | usd |
CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4174985 | usd |
CY2024Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | usd |
CY2023Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
153 | usd |
CY2024Q1 | drma |
Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
|
0 | usd |
CY2023Q1 | drma |
Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
|
40 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4175098 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-2704454 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
2525465 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7438135 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
6241294 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
4733681 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
8766759 | usd |
CY2024Q1 | drma |
Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
|
-273 | usd |
CY2023Q1 | drma |
Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
|
0 | usd |
CY2024Q1 | drma |
Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
|
0 | usd |
CY2023Q1 | drma |
Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
|
144765 | usd |
CY2021Q3 | us-gaap |
Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
|
24106 | shares |
CY2021Q3 | drma |
Class Of Warrant Or Right Exercise Price Of Warrants Or Right
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight
|
112.00 | |
CY2024Q1 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
4700000 | usd |
CY2024Q1 | us-gaap |
Cumulative Earnings Deficit
CumulativeEarningsDeficit
|
56500000 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
2700000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
6400000 | usd |
CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8768940 | shares |
CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3888691 | shares |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
2.82 | |
CY2023Q4 | drma |
Offering Expenses
OfferingExpenses
|
300000 | usd |
CY2024Q1 | drma |
Description Of Abeyance Shares
DescriptionOfAbeyanceShares
|
the Holder left 2,730,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request, which were then delivered to the Holder on January 8, 2024 | |
CY2023Q2 | drma |
Proceeds Cash From Pipe
ProceedsCashFromPipe
|
1500000 | usd |
CY2023Q2 | drma |
Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
|
300000 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0.0001 | |
CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
8358697 | shares |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
8358697 | shares |
CY2023Q4 | drma |
Warrants To Purchase Up To Shares Of Common Stock
WarrantsToPurchaseUpToSharesOfCommonStock
|
3472095 | shares |
CY2023Q4 | drma |
Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
|
0.6511 | |
CY2023Q4 | drma |
Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
|
0.6511 | |
CY2023Q4 | drma |
Received Net Cash Proceeds
ReceivedNetCashProceeds
|
2000000.0 | usd |
CY2024Q1 | drma |
Warrant Reduced Description
WarrantReducedDescription
|
from $21.20 to $2.82 per share upon closing of the March 2023 Offering | |
CY2024Q1 | drma |
Description Of Stock Option Cancellation
DescriptionOfStockOptionCancellation
|
in accordance with an option cancellation agreement. Accordingly, 101,831 of the 102,074 stock options outstanding as of December 31, 2023, were cancelled in February 2024 | |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
568372 | usd |
CY2024Q1 | drma |
Common Stock Par Or Stated Values Per Share
CommonStockParOrStatedValuesPerShare
|
0.4108 | |
CY2024Q1 | us-gaap |
Contractually Specified Servicing Fees Amount
ContractuallySpecifiedServicingFeesAmount
|
6900000 | usd |
CY2024Q1 | us-gaap |
Other Expenses
OtherExpenses
|
1400000 | usd |